Page last updated: 2024-09-03

piperaquine and 2019 Novel Coronavirus Disease

piperaquine has been researched along with 2019 Novel Coronavirus Disease in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Baraka, V; Francis, F; Geertruyden, JV; Gesase, S; Kyaruzi, E; Lusingu, JPA; Madebe, R; Makenga, G; Minja, DTR; Mtove, G; Nakato, S	1

Trials

1 trial(s) available for piperaquine and 2019 Novel Coronavirus Disease

Article	Year
Effectiveness and safety of intermittent preventive treatment with dihydroartemisinin-piperaquine or artesunate-amodiaquine for reducing malaria and related morbidities in schoolchildren in Tanzania: a randomised controlled trial. The Lancet. Global health, 2023, Volume: 11, Issue:8 Topics: Amodiaquine; Antimalarials; Artesunate; Child; COVID-19; Drug Combinations; Hemoglobins; Humans; Incidence; Malaria; Malaria, Falciparum; Quinolines; Tanzania	2023

Article

Year

Effectiveness and safety of intermittent preventive treatment with dihydroartemisinin-piperaquine or artesunate-amodiaquine for reducing malaria and related morbidities in schoolchildren in Tanzania: a randomised controlled trial.

The Lancet. Global health, 2023, Volume: 11, Issue:8

Topics: Amodiaquine; Antimalarials; Artesunate; Child; COVID-19; Drug Combinations; Hemoglobins; Humans; Incidence; Malaria; Malaria, Falciparum; Quinolines; Tanzania

2023